Pharma’s internal innovation units often look externally for ideas that can transform the business. Here, the director of Pfizer’s worldwide innovation group describes how he imported an approach to help sustain skill development within the network.
Valeant’s controversial model undergoing changes, says CEO
The drugmaker, which recently drew scrutiny from lawmakers, is planning to change some of its most contentious business practices. Experts say Valeant also needs to educate lawmakers and the public about the value of its medicines.
Five things for pharma marketers to know: Wednesday, October 14, 2015
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies
Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals
By thinking like marketers, chief medical officers can embrace innovation and differentiate their organizations by providing better experiences, better products and ultimately better health.
Savvy comms paves way for Walgreens Boots Alliance merger
Walgreens Boots Alliance’s global comms team works hand in hand to balance the complexities of a merger and create a unified strategy to inspire all stakeholders.